Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non‐small cell lung cancer (NSCLC) compared with chemotherapy (Quijote‐CLICaP)
Background: To compare survival outcomes of patients with advanced or metastatic non-small cell lung cancer (NSCLC) who received immunotherapy as first-, second- or beyond line, versus matched patients receiving standard chemotherapy with special characterization of hyperprogressors. Methods: A retr...
- Autores:
-
Ruiz-Patinõ, Alejandro
Arrieta, Oscar
Cardona-Mendoza, Andrés Felipe
Martín, Claudio Marcelo
Raez, Luis Estuardo
Zatarain-Barrón, Zyanya Lucia
Barron, Feliciano
Ricaurte, Luisa María
Bravo-Garzón, María A.
Mas, Luis A.
Corrales, Luis
Rojas Puentes, Leonardo
Lupinacci, Lorena
Perazzo, Florencia
Bas, Carlos Arturo
Carranza, Omar E.
Puparelli, Carmen
Rizzo, Miguel M
Ruiz, Rossana
Rolfo, Christian
Archila, Pilar
Rodríguez, July F.
Vargas Báez, Carlos Alberto
Carranza, Hernán
Otero, Jorge Miguel
Pino, Luis Eduardo
Ortíz, Carlos
Laguado, Paola
Rosell, Rafael Costa
- Tipo de recurso:
- Fecha de publicación:
- 2020
- Institución:
- Universidad El Bosque
- Repositorio:
- Repositorio U. El Bosque
- Idioma:
- eng
- OAI Identifier:
- oai:repositorio.unbosque.edu.co:20.500.12495/2022
- Palabra clave:
- Estadificación de neoplasias
Sistema nervioso central
Estudios de cohortes
Adult
Immunotherapy
Lung neoplasms
- Rights
- License
- Attribution 4.0 International
id |
UNBOSQUE2_fbcff39a05f5a4ff4f991f04958053f0 |
---|---|
oai_identifier_str |
oai:repositorio.unbosque.edu.co:20.500.12495/2022 |
network_acronym_str |
UNBOSQUE2 |
network_name_str |
Repositorio U. El Bosque |
repository_id_str |
|
dc.title.spa.fl_str_mv |
Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non‐small cell lung cancer (NSCLC) compared with chemotherapy (Quijote‐CLICaP) |
dc.title.translated.none.fl_str_mv |
Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non‐small cell lung cancer (NSCLC) compared with chemotherapy (Quijote‐CLICaP) |
title |
Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non‐small cell lung cancer (NSCLC) compared with chemotherapy (Quijote‐CLICaP) |
spellingShingle |
Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non‐small cell lung cancer (NSCLC) compared with chemotherapy (Quijote‐CLICaP) Estadificación de neoplasias Sistema nervioso central Estudios de cohortes Adult Immunotherapy Lung neoplasms |
title_short |
Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non‐small cell lung cancer (NSCLC) compared with chemotherapy (Quijote‐CLICaP) |
title_full |
Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non‐small cell lung cancer (NSCLC) compared with chemotherapy (Quijote‐CLICaP) |
title_fullStr |
Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non‐small cell lung cancer (NSCLC) compared with chemotherapy (Quijote‐CLICaP) |
title_full_unstemmed |
Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non‐small cell lung cancer (NSCLC) compared with chemotherapy (Quijote‐CLICaP) |
title_sort |
Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non‐small cell lung cancer (NSCLC) compared with chemotherapy (Quijote‐CLICaP) |
dc.creator.fl_str_mv |
Ruiz-Patinõ, Alejandro Arrieta, Oscar Cardona-Mendoza, Andrés Felipe Martín, Claudio Marcelo Raez, Luis Estuardo Zatarain-Barrón, Zyanya Lucia Barron, Feliciano Ricaurte, Luisa María Bravo-Garzón, María A. Mas, Luis A. Corrales, Luis Rojas Puentes, Leonardo Lupinacci, Lorena Perazzo, Florencia Bas, Carlos Arturo Carranza, Omar E. Puparelli, Carmen Rizzo, Miguel M Ruiz, Rossana Rolfo, Christian Archila, Pilar Rodríguez, July F. Vargas Báez, Carlos Alberto Carranza, Hernán Otero, Jorge Miguel Pino, Luis Eduardo Ortíz, Carlos Laguado, Paola Rosell, Rafael Costa |
dc.contributor.author.none.fl_str_mv |
Ruiz-Patinõ, Alejandro Arrieta, Oscar Cardona-Mendoza, Andrés Felipe Martín, Claudio Marcelo Raez, Luis Estuardo Zatarain-Barrón, Zyanya Lucia Barron, Feliciano Ricaurte, Luisa María Bravo-Garzón, María A. Mas, Luis A. Corrales, Luis Rojas Puentes, Leonardo Lupinacci, Lorena Perazzo, Florencia Bas, Carlos Arturo Carranza, Omar E. Puparelli, Carmen Rizzo, Miguel M Ruiz, Rossana Rolfo, Christian Archila, Pilar Rodríguez, July F. Vargas Báez, Carlos Alberto Carranza, Hernán Otero, Jorge Miguel Pino, Luis Eduardo Ortíz, Carlos Laguado, Paola Rosell, Rafael Costa |
dc.contributor.orcid.none.fl_str_mv |
Cardona-Mendoza, Andrés Felipe [0000-0002-6697-5471] Vargas Báez, Carlos Alberto [0000-0002-6076-8260] Rojas Puentes, Leonardo [0000-0002-7865-5424] |
dc.subject.decs.spa.fl_str_mv |
Estadificación de neoplasias Sistema nervioso central Estudios de cohortes |
topic |
Estadificación de neoplasias Sistema nervioso central Estudios de cohortes Adult Immunotherapy Lung neoplasms |
dc.subject.keywords.spa.fl_str_mv |
Adult Immunotherapy Lung neoplasms |
description |
Background: To compare survival outcomes of patients with advanced or metastatic non-small cell lung cancer (NSCLC) who received immunotherapy as first-, second- or beyond line, versus matched patients receiving standard chemotherapy with special characterization of hyperprogressors. Methods: A retrospective cohort study of 296 patients with unresectable/metastatic NSCLC treated with either, first-, second-, third- or fourth-line of immunotherapy was conducted. A matched comparison with a historical cohort of first-line chemotherapy and a random forest tree analysis to characterize hyperprogressors was conducted. Results: Median age was 64 years (range 34–90), 40.2% of patients were female. A total of 91.2% of patients had an Eastern Cooperative Oncology Group (ECOG) performance score ≤ 1. Immunotherapy as first-line was given to 39 patients (13.7%), second-line to 140 (48.8%), and as third-line and beyond to 108 (37.6%). Median overall survival was 12.7 months (95% CI 9.67–14 months) and progression-free survival (PFS) of 4.27 months (95% CI 3.97–5.0). Factors associated with increased survival included treatment with immunotherapy as first-line (P < 0.001), type of response (P < 0.001) and PD-L1 status (P = 0.0039). Compared with the historical cohort, immunotherapy proved to be superior in terms of OS (P = 0.05) but not PFS (P = 0.2). A total of 44 hyperprogressors were documented (19.8%, [95% CI 14.5–25.1%]). Leukocyte count over 5.300 cells/dL was present in both hyperprogressors and long-term responders. Conclusions: Patients who receive immune-checkpoint inhibitors as part of their treatment for NSCLC have better overall survival (OS) compared with matched patients treated with standard chemotherapy, regardless of the line of treatment. |
publishDate |
2020 |
dc.date.accessioned.none.fl_str_mv |
2020-03-09T15:30:12Z |
dc.date.available.none.fl_str_mv |
2020-03-09T15:30:12Z |
dc.date.issued.none.fl_str_mv |
2020 |
dc.type.spa.fl_str_mv |
article |
dc.type.coarversion.fl_str_mv |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
dc.type.coar.fl_str_mv |
http://purl.org/coar/resource_type/c_6501 |
dc.type.local.spa.fl_str_mv |
artículo |
dc.identifier.issn.none.fl_str_mv |
1759-7706 |
dc.identifier.uri.none.fl_str_mv |
http://hdl.handle.net/20.500.12495/2022 |
dc.identifier.doi.none.fl_str_mv |
https://doi.org/10.1111/1759-7714.13272 |
dc.identifier.instname.spa.fl_str_mv |
instname:Universidad El Bosque |
dc.identifier.reponame.spa.fl_str_mv |
reponame:Repositorio Institucional Universidad El Bosque |
dc.identifier.repourl.none.fl_str_mv |
repourl:https://repositorio.unbosque.edu.co |
identifier_str_mv |
1759-7706 instname:Universidad El Bosque reponame:Repositorio Institucional Universidad El Bosque repourl:https://repositorio.unbosque.edu.co |
url |
http://hdl.handle.net/20.500.12495/2022 https://doi.org/10.1111/1759-7714.13272 |
dc.language.iso.none.fl_str_mv |
eng |
language |
eng |
dc.relation.ispartofseries.spa.fl_str_mv |
Thoracic Cancer, 1759-7706, Vol. 11, Nro. 2, 2020, p. 353-361 |
dc.relation.uri.none.fl_str_mv |
https://onlinelibrary.wiley.com/doi/full/10.1111/1759-7714.13272 |
dc.rights.*.fl_str_mv |
Attribution 4.0 International |
dc.rights.coar.fl_str_mv |
http://purl.org/coar/access_right/c_abf2 |
dc.rights.uri.*.fl_str_mv |
http://creativecommons.org/licenses/by/4.0/ |
dc.rights.local.spa.fl_str_mv |
Acceso abierto |
dc.rights.accessrights.none.fl_str_mv |
http://purl.org/coar/access_right/c_abf304 |
dc.rights.creativecommons.none.fl_str_mv |
2020 |
rights_invalid_str_mv |
Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ Acceso abierto http://purl.org/coar/access_right/c_abf304 2020 http://purl.org/coar/access_right/c_abf2 |
dc.format.mimetype.none.fl_str_mv |
application/pdf |
dc.publisher.spa.fl_str_mv |
Wiley-Blackwell |
dc.publisher.journal.spa.fl_str_mv |
Thoracic Cancer |
institution |
Universidad El Bosque |
bitstream.url.fl_str_mv |
http://18.204.144.38/bitstreams/ab7d0010-8bfa-4603-8121-56f02938afed/download http://18.204.144.38/bitstreams/d457fdaa-5a07-4f38-8332-b5892d84151f/download http://18.204.144.38/bitstreams/f369dc99-a223-4b00-98a4-5682b8470cc7/download http://18.204.144.38/bitstreams/9f292f5c-9458-43e5-a930-907ab20b25f9/download http://18.204.144.38/bitstreams/811e6655-282e-4d4a-91d3-4fd7633c927a/download |
bitstream.checksum.fl_str_mv |
0128858feff282eee4d6e91fa44b6023 0175ea4a2d4caec4bbcc37e300941108 8a4605be74aa9ea9d79846c1fba20a33 1848036acb631475dc44bb0ccbe05b72 375d341ea09f569f08094f1446a29d0b |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 MD5 MD5 |
repository.name.fl_str_mv |
DSpace Pre-instalado Biteca S.A.S |
repository.mail.fl_str_mv |
bibliotecas@biteca.com |
_version_ |
1814100679983104000 |
spelling |
Ruiz-Patinõ, AlejandroArrieta, OscarCardona-Mendoza, Andrés FelipeMartín, Claudio MarceloRaez, Luis EstuardoZatarain-Barrón, Zyanya LuciaBarron, FelicianoRicaurte, Luisa MaríaBravo-Garzón, María A.Mas, Luis A.Corrales, LuisRojas Puentes, LeonardoLupinacci, LorenaPerazzo, FlorenciaBas, Carlos ArturoCarranza, Omar E.Puparelli, CarmenRizzo, Miguel MRuiz, RossanaRolfo, ChristianArchila, PilarRodríguez, July F.Vargas Báez, Carlos AlbertoCarranza, HernánOtero, Jorge MiguelPino, Luis EduardoOrtíz, CarlosLaguado, PaolaRosell, Rafael CostaCardona-Mendoza, Andrés Felipe [0000-0002-6697-5471]Vargas Báez, Carlos Alberto [0000-0002-6076-8260]Rojas Puentes, Leonardo [0000-0002-7865-5424]2020-03-09T15:30:12Z2020-03-09T15:30:12Z20201759-7706http://hdl.handle.net/20.500.12495/2022https://doi.org/10.1111/1759-7714.13272instname:Universidad El Bosquereponame:Repositorio Institucional Universidad El Bosquerepourl:https://repositorio.unbosque.edu.coapplication/pdfengWiley-BlackwellThoracic CancerThoracic Cancer, 1759-7706, Vol. 11, Nro. 2, 2020, p. 353-361https://onlinelibrary.wiley.com/doi/full/10.1111/1759-7714.13272Attribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/Acceso abiertohttp://purl.org/coar/access_right/c_abf3042020http://purl.org/coar/access_right/c_abf2Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non‐small cell lung cancer (NSCLC) compared with chemotherapy (Quijote‐CLICaP)Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non‐small cell lung cancer (NSCLC) compared with chemotherapy (Quijote‐CLICaP)articleartículohttp://purl.org/coar/version/c_970fb48d4fbd8a85http://purl.org/coar/resource_type/c_6501Estadificación de neoplasiasSistema nervioso centralEstudios de cohortesAdultImmunotherapyLung neoplasmsBackground: To compare survival outcomes of patients with advanced or metastatic non-small cell lung cancer (NSCLC) who received immunotherapy as first-, second- or beyond line, versus matched patients receiving standard chemotherapy with special characterization of hyperprogressors. Methods: A retrospective cohort study of 296 patients with unresectable/metastatic NSCLC treated with either, first-, second-, third- or fourth-line of immunotherapy was conducted. A matched comparison with a historical cohort of first-line chemotherapy and a random forest tree analysis to characterize hyperprogressors was conducted. Results: Median age was 64 years (range 34–90), 40.2% of patients were female. A total of 91.2% of patients had an Eastern Cooperative Oncology Group (ECOG) performance score ≤ 1. Immunotherapy as first-line was given to 39 patients (13.7%), second-line to 140 (48.8%), and as third-line and beyond to 108 (37.6%). Median overall survival was 12.7 months (95% CI 9.67–14 months) and progression-free survival (PFS) of 4.27 months (95% CI 3.97–5.0). Factors associated with increased survival included treatment with immunotherapy as first-line (P < 0.001), type of response (P < 0.001) and PD-L1 status (P = 0.0039). Compared with the historical cohort, immunotherapy proved to be superior in terms of OS (P = 0.05) but not PFS (P = 0.2). A total of 44 hyperprogressors were documented (19.8%, [95% CI 14.5–25.1%]). Leukocyte count over 5.300 cells/dL was present in both hyperprogressors and long-term responders. Conclusions: Patients who receive immune-checkpoint inhibitors as part of their treatment for NSCLC have better overall survival (OS) compared with matched patients treated with standard chemotherapy, regardless of the line of treatment.ORIGINALRuiz-Patinõ, Alejandro_2020.pdfRuiz-Patinõ, Alejandro_2020.pdfapplication/pdf739530http://18.204.144.38/bitstreams/ab7d0010-8bfa-4603-8121-56f02938afed/download0128858feff282eee4d6e91fa44b6023MD51CC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-8908http://18.204.144.38/bitstreams/d457fdaa-5a07-4f38-8332-b5892d84151f/download0175ea4a2d4caec4bbcc37e300941108MD52LICENSElicense.txtlicense.txttext/plain; charset=utf-81748http://18.204.144.38/bitstreams/f369dc99-a223-4b00-98a4-5682b8470cc7/download8a4605be74aa9ea9d79846c1fba20a33MD53THUMBNAILRuiz-Patinõ, Alejandro_2020.pdf.jpgRuiz-Patinõ, Alejandro_2020.pdf.jpgIM Thumbnailimage/jpeg9712http://18.204.144.38/bitstreams/9f292f5c-9458-43e5-a930-907ab20b25f9/download1848036acb631475dc44bb0ccbe05b72MD54TEXTRuiz-Patinõ, Alejandro_2020.pdf.txtRuiz-Patinõ, Alejandro_2020.pdf.txtExtracted texttext/plain40819http://18.204.144.38/bitstreams/811e6655-282e-4d4a-91d3-4fd7633c927a/download375d341ea09f569f08094f1446a29d0bMD5520.500.12495/2022oai:18.204.144.38:20.500.12495/20222024-02-06 22:12:25.126http://creativecommons.org/licenses/by/4.0/Attribution 4.0 Internationalopen.accesshttp://18.204.144.38DSpace Pre-instalado Biteca S.A.Sbibliotecas@biteca.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 |